Center of Clinical Pharmacology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Anesthesiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Clin Transl Sci. 2023 Oct;16(10):1972-1981. doi: 10.1111/cts.13605. Epub 2023 Aug 10.
Ciprofol (also known as HSK3486) is a promising intravenous anesthetic candidate derived from propofol and independently developed by Haisco Pharmaceutical Group Co., Ltd. (Chengdu, China). Compared with propofol, ciprofol has the potential to reduce the dose required and the associated risks. Ciprofol is extensively metabolized in vivo, and its interaction with other concurrently administered drugs during clinical application is worthy of attention. Therefore, an open-label, two-stage sequential study was performed in healthy subjects who received either a single administration of ciprofol injection or ciprofol injection after oral administration of sodium divalproex. The aim of the study was to evaluate the effects of sodium divalproex on ciprofol with respect to pharmacokinetics, pharmacodynamics, and safety, thus providing a basis for the rational clinical use of ciprofol and sodium divalproex.
西普罗夫（又称 HSK3486）是一种有前途的静脉麻醉候选药物，由丙泊酚衍生而来，由豪斯制药集团有限公司（中国成都）独立开发。与丙泊酚相比，西普罗夫有可能降低所需剂量和相关风险。西普罗夫在体内广泛代谢，其在临床应用中与同时给予的其他药物的相互作用值得关注。因此，在接受西普罗夫注射或西普罗夫注射后口服丙戊酸钠的健康受试者中进行了一项开放标签、两阶段序贯研究。该研究的目的是评估丙戊酸钠对西普罗夫药代动力学、药效学和安全性的影响，从而为西普罗夫和丙戊酸钠的合理临床应用提供依据。
